Adenosine A2A analogue improves neurologic outcome after supinal cord trauma in the rabbit

David C. Cassada, Curtis G. Tribble, Jeffrey S. Young, James J. Gangemi, A. Reza Gohari, Paris D. Butler, Jayson M. Rieger, Irving L. Kron, Joel Linden, John A. Kern

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Background ATL-146e, an adenosine A2A agonist, reduces paralysis after supinal cord ischemia-reperfusion. We hypothesized that systemic ATL-146e could improve neurologic outcome after blunt supinal cord trauma. Methods Twenty rabbits survived a thoracic supinal cord impact of 30 g-cm. One group received 0.06 μg/kg/min ATL-146e for the first 3 hours after impact (A2A group), whereas a second group received saline carrier (T/C group). Neurologic outcome was measured using the Tarlov scale (0-5). Histologic sections from the A2A and T/C groups were compared for neuronal viability. Results There was significant improvement in Tarlov scores of A2A animals compared with T/C animals at 12 hours (p = 0.007), with a trend toward improvement at 36 (p = 0.08) and 48 (p = 0.09) hours after injury. There was decreased neuronal attrition in A2A animals (p = 0.06). Conclusion Systemic ATL-146e given after supinal cord trauma results in improved neurologic outcome. Adenosine A2A agonists may hold promise as a rapidly acting alternative to steroids in the early treatment of the supinal cord injured patient.

Original languageEnglish (US)
Pages (from-to)225-231
Number of pages7
JournalJournal of Trauma
Issue number2
StatePublished - Aug 2002


  • Adenosine
  • Preconditioning
  • supinal cord trauma

ASJC Scopus subject areas

  • Surgery
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Adenosine A2A analogue improves neurologic outcome after supinal cord trauma in the rabbit'. Together they form a unique fingerprint.

Cite this